Effect of risedronate on femoral periprosthetic bone loss following total hip replacement: A systematic review and meta-analysis.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
osteoporosis 3 endocrinologydiseases
zoledronic acid 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
zoledronic acid 2791 around the stems and implant stability. Gao et al[[9]] reported that intravenous administration of zoledronic acid could significantly reduce periprosthetic BMD loss after THA without severe adverse events. Risedronate
Select Disease Character Offset Disease Term Instance
osteoporosis 2980 severe adverse events. Risedronate is an orally, administered bisphosphonate used for the prevention of osteoporosis , and Paget's disease.[[10],[11]] Recent study has reported that risedronate was effective in reducing
osteoporosis 15310 is applied to inhibit bone resorption, and have been widely, used for treatment, and prevention of osteoporosis . Previous studies demonstrated that the anti-osteoporosis effect could last as long as 1 year after
osteoporosis 15368 widely, used for treatment, and prevention of osteoporosis. Previous studies demonstrated that the anti- osteoporosis effect could last as long as 1 year after arthroplasty.[[23]] In our study, dual-energy X-ray device

You must be authorized to submit a review.